Bharat Biotech commences direct supply of COVID-19 vaccine Covaxin to 14 States

Bharat Biotech has started supplying its COVID-19 treatment vaccine to the States based on the allocations received by the Central government

Published - May 10, 2021 12:58 pm IST - New Delhi

On April 29, Bharat Biotech announced a cut in the price of 'Covaxin' for States to ₹400 per dose from the earlier ₹600 per dose. File

On April 29, Bharat Biotech announced a cut in the price of 'Covaxin' for States to ₹400 per dose from the earlier ₹600 per dose. File

Bharat Biotech has commenced direct supply of its COVID-19 vaccine ‘Covaxin’ to 14 States, including Delhi and Maharashtra, with effect from May 1, according to the company’s Joint Managing Director Suchitra Ella.

The Hyderabad-based firm has started supplying its COVID-19 treatment vaccine to the States based on the allocations received by the Central government.

“Bharat Biotech confirms direct supplies of COVAXIN to the following State govt’s since 1/5/21, based on the allocations received by GoI. Requests have been received from other States, & will be processed for distribution based on availability of stocks 24x7,” Ms. Ella tweeted.

The company is supplying vaccines to Andhra Pradesh, Assam, Chhattisgarh, Gujarat, Jammu & Kashmir, Jharkhand, Madhya Pradesh, Odisha, Tamil Nadu, Telangana, Uttar Pradesh and West Bengal.

On April 29, Bharat Biotech announced a cut in the price of ‘Covaxin’ for States to ₹400 per dose from the earlier ₹600 per dose.

This followed widespread criticism of its pricing policy as it sold Covaxin to the Central government at ₹150 per dose.

India has announced expansion of its COVID-19 vaccination drive by allowing its large 18-plus population to get inoculated from May 1.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.